RE:RE:RE:RE:RE:RE:RE:RE:RE:Credit Suisse event now availableWe did hope there would be better sale numbers due to dual effect of Egrifta but it is based on clinical trials which are not approved so there are obviously some hesitation there but if their drug get approved for general population for an unmet serious condition there won't be a need to convince doctors and patients as that would no other options even so others drugs get approved before there will be a market for Egrifta as the disease is heterogeneous because not all drugs work for all the patients.
jeffm34 wrote: If THTX can't convince physicians to prescribe egrifta now to treat and prevent NASH in their HIV patients. (which they could be doing) why would you expect them to do any better in the general population?